TRex Bio Shares Dip After $116.7 Million IPO Pricing at Low End of Range
The clinical-stage biotech raised the capital by selling 8.3 million shares at $14 each, its trading debut followed a slight decline.
The story so far
2 publishers have covered this in 2 articles since 9 Oct 2026. Quartz published first, on 9 October at 12:00 UTC; Bloomberg.com followed 4h 03m later. The most recent article, from Bloomberg.com, appeared on 9 October at 16:03 UTC.
Outlets reporting it: Bloomberg.com (major outlet), Quartz.
No prediction market is linked to this story at the moment. We match each story to Polymarket and Kalshi markets by what they ask, and show one only when it is close enough to be useful; if a market on this topic opens, it will appear here. Meanwhile, browse every market we track or see how stories and markets are matched.
Sources
Every article we clustered into this story. Headlines link to the publisher.
In this story
- TRex Bio Inc.
- Eli Lilly